Early clinical results with the Tendyne transcatheter mitral valve replacement system

Jared P. Beller, Jason H Rogers, Vinod H. Thourani, Gorav Ailawadi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Transcatheter mitral valve replacement is an emerging technology for the treatment of mitral valve regurgitation. Numerous devices are in development and in various stages of clinical investigation. The Tendyne system (Tendyne Holdings, LLC, a subsidiary of Abbott Vascular, Roseville, Minnesota) is a fully repositionable and retrievable, transapical transcatheter mitral valve replacement platform. The results of the early feasibility studies in the U.S. are highly encouraging and a pivotal randomized trial is underway. The Tendyne transcatheter mitral valve replacement valve may prove to be a safe, less invasive approach to treatment of mitral valve disease.

Original languageEnglish (US)
Pages (from-to)776-779
Number of pages4
JournalAnnals of Cardiothoracic Surgery
Volume7
Issue number6
DOIs
StatePublished - Nov 1 2018

Fingerprint

Mitral Valve
Mitral Valve Insufficiency
Feasibility Studies
Blood Vessels
Technology
Equipment and Supplies

Keywords

  • Mitral valve regurgitation
  • Tendyne
  • Transcatheter mitral valve replacement (TMVR)

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Early clinical results with the Tendyne transcatheter mitral valve replacement system. / Beller, Jared P.; Rogers, Jason H; Thourani, Vinod H.; Ailawadi, Gorav.

In: Annals of Cardiothoracic Surgery, Vol. 7, No. 6, 01.11.2018, p. 776-779.

Research output: Contribution to journalArticle

Beller, Jared P. ; Rogers, Jason H ; Thourani, Vinod H. ; Ailawadi, Gorav. / Early clinical results with the Tendyne transcatheter mitral valve replacement system. In: Annals of Cardiothoracic Surgery. 2018 ; Vol. 7, No. 6. pp. 776-779.
@article{0d536fb90c164a8c8419e92f77db29eb,
title = "Early clinical results with the Tendyne transcatheter mitral valve replacement system",
abstract = "Transcatheter mitral valve replacement is an emerging technology for the treatment of mitral valve regurgitation. Numerous devices are in development and in various stages of clinical investigation. The Tendyne system (Tendyne Holdings, LLC, a subsidiary of Abbott Vascular, Roseville, Minnesota) is a fully repositionable and retrievable, transapical transcatheter mitral valve replacement platform. The results of the early feasibility studies in the U.S. are highly encouraging and a pivotal randomized trial is underway. The Tendyne transcatheter mitral valve replacement valve may prove to be a safe, less invasive approach to treatment of mitral valve disease.",
keywords = "Mitral valve regurgitation, Tendyne, Transcatheter mitral valve replacement (TMVR)",
author = "Beller, {Jared P.} and Rogers, {Jason H} and Thourani, {Vinod H.} and Gorav Ailawadi",
year = "2018",
month = "11",
day = "1",
doi = "10.21037/acs.2018.10.01",
language = "English (US)",
volume = "7",
pages = "776--779",
journal = "Annals of Cardiothoracic Surgery",
issn = "2225-319X",
publisher = "AME Publishing Company",
number = "6",

}

TY - JOUR

T1 - Early clinical results with the Tendyne transcatheter mitral valve replacement system

AU - Beller, Jared P.

AU - Rogers, Jason H

AU - Thourani, Vinod H.

AU - Ailawadi, Gorav

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Transcatheter mitral valve replacement is an emerging technology for the treatment of mitral valve regurgitation. Numerous devices are in development and in various stages of clinical investigation. The Tendyne system (Tendyne Holdings, LLC, a subsidiary of Abbott Vascular, Roseville, Minnesota) is a fully repositionable and retrievable, transapical transcatheter mitral valve replacement platform. The results of the early feasibility studies in the U.S. are highly encouraging and a pivotal randomized trial is underway. The Tendyne transcatheter mitral valve replacement valve may prove to be a safe, less invasive approach to treatment of mitral valve disease.

AB - Transcatheter mitral valve replacement is an emerging technology for the treatment of mitral valve regurgitation. Numerous devices are in development and in various stages of clinical investigation. The Tendyne system (Tendyne Holdings, LLC, a subsidiary of Abbott Vascular, Roseville, Minnesota) is a fully repositionable and retrievable, transapical transcatheter mitral valve replacement platform. The results of the early feasibility studies in the U.S. are highly encouraging and a pivotal randomized trial is underway. The Tendyne transcatheter mitral valve replacement valve may prove to be a safe, less invasive approach to treatment of mitral valve disease.

KW - Mitral valve regurgitation

KW - Tendyne

KW - Transcatheter mitral valve replacement (TMVR)

UR - http://www.scopus.com/inward/record.url?scp=85057722448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057722448&partnerID=8YFLogxK

U2 - 10.21037/acs.2018.10.01

DO - 10.21037/acs.2018.10.01

M3 - Article

VL - 7

SP - 776

EP - 779

JO - Annals of Cardiothoracic Surgery

JF - Annals of Cardiothoracic Surgery

SN - 2225-319X

IS - 6

ER -